Gold-based nanomaterials with plasmonic properties exhibit various potentials for biomedical applications. In this work, gold nanoprisms (GNPs) was synthesized and then modified with LyP-1, a tumor-homing peptide, to ...Gold-based nanomaterials with plasmonic properties exhibit various potentials for biomedical applications. In this work, gold nanoprisms (GNPs) was synthesized and then modified with LyP-1, a tumor-homing peptide, to improve the affinity of the GNPs to tumor cells, thus, to improve the efficacy of tumor-targeted photothermal therapy. The introduction of NIR dye IR780 not only enabled the GNPs-based nanosystem with the surface-enhanced resonant Raman scattering (SERRS) property, but also enhanced the plasmonic photothermal property which delivering therapeutic heating by 660 nm laser irradiation. The obtained GNPs/IR780-LyP-1 presented significantly increased of photothermal conversion in vitro and in vivo, which resulted in enhanced tumor-targeting photothermal therapeutic efficacy after laser irradiation. Hence, the GNPs/IR780-LyP-1 prepared in this study can be served as a Raman-encoded molecular imaging candidate and photothermal therapy agents for future cancer treatment.展开更多
Background Recent studies have shown the LyP-1 peptide can home to either tumor lymphatics or the tumor cells and be internalized by targeted cells. This study aimed to investigate the possibility of using Na1311 labe...Background Recent studies have shown the LyP-1 peptide can home to either tumor lymphatics or the tumor cells and be internalized by targeted cells. This study aimed to investigate the possibility of using Na1311 labeled LyP-1 peptide as an imaging agent or a therapeutic radiopharmaceutical in breast carcinoma and its metastasis. Methods The 10-mer cyclic peptide contained the LyP-1 sequence （YCGNKRTRGC） was synthesized by the solid phase method. Disulfide bonds between the cysteines maintain the cyclic structure. The LyP-1 peptide was labeled with Na1311 using the chloramine-T method. The [1311] LyP-1 peptide and a [1311] control peptide were injected via tail vein into nude mice bearing MDA-MB-435 tumor xenografts. Biodistribution and imaging results in vivo were obtained. Results The labeling efficiencies of LyP-1 peptide reached 80%＋5% （n=5）. The radiochemical purity was about 96%. The radiochemical purity of the labeled compound remains 92% at 24 hours in human serum at 37~C. In the biodistribution studies, the [1311] LyP-1 peptide accumulated in the tumor to a higher level than in other organs. The [1311] LyP-1 peptide can successfully image the tumor in nude mice bearing MDA-MB-435 tumor xenografts. Conclusions The LyP-1 peptide could be effectively labeled with Na1311 and the labeled compound is stable in human serum at 37℃ for 24 hours. The high specificity of [1311] LyP-1 peptide suggests it may be a promising new radiotracer for identifying tumors.展开更多
基金financially supported by the Application Fundamental Research Foundation of Sichuan Province Science and Technology Department, China (No. 2016JY0157)the State Sponsored Scholarship for Visiting Scholar from China Scholarship Council, the Outstanding Science and Technology Projects for Returned Overseas Chinese Scholars, Sichuan Province, China, theNational Natural Science Foundation of China (No. 31600811) the National Training Program of Innovation and Entrepreneurship for Undergraduates(No. 201813705025)
文摘Gold-based nanomaterials with plasmonic properties exhibit various potentials for biomedical applications. In this work, gold nanoprisms (GNPs) was synthesized and then modified with LyP-1, a tumor-homing peptide, to improve the affinity of the GNPs to tumor cells, thus, to improve the efficacy of tumor-targeted photothermal therapy. The introduction of NIR dye IR780 not only enabled the GNPs-based nanosystem with the surface-enhanced resonant Raman scattering (SERRS) property, but also enhanced the plasmonic photothermal property which delivering therapeutic heating by 660 nm laser irradiation. The obtained GNPs/IR780-LyP-1 presented significantly increased of photothermal conversion in vitro and in vivo, which resulted in enhanced tumor-targeting photothermal therapeutic efficacy after laser irradiation. Hence, the GNPs/IR780-LyP-1 prepared in this study can be served as a Raman-encoded molecular imaging candidate and photothermal therapy agents for future cancer treatment.
文摘Background Recent studies have shown the LyP-1 peptide can home to either tumor lymphatics or the tumor cells and be internalized by targeted cells. This study aimed to investigate the possibility of using Na1311 labeled LyP-1 peptide as an imaging agent or a therapeutic radiopharmaceutical in breast carcinoma and its metastasis. Methods The 10-mer cyclic peptide contained the LyP-1 sequence （YCGNKRTRGC） was synthesized by the solid phase method. Disulfide bonds between the cysteines maintain the cyclic structure. The LyP-1 peptide was labeled with Na1311 using the chloramine-T method. The [1311] LyP-1 peptide and a [1311] control peptide were injected via tail vein into nude mice bearing MDA-MB-435 tumor xenografts. Biodistribution and imaging results in vivo were obtained. Results The labeling efficiencies of LyP-1 peptide reached 80%＋5% （n=5）. The radiochemical purity was about 96%. The radiochemical purity of the labeled compound remains 92% at 24 hours in human serum at 37~C. In the biodistribution studies, the [1311] LyP-1 peptide accumulated in the tumor to a higher level than in other organs. The [1311] LyP-1 peptide can successfully image the tumor in nude mice bearing MDA-MB-435 tumor xenografts. Conclusions The LyP-1 peptide could be effectively labeled with Na1311 and the labeled compound is stable in human serum at 37℃ for 24 hours. The high specificity of [1311] LyP-1 peptide suggests it may be a promising new radiotracer for identifying tumors.
